The Novel Dual-Targeted Therapy for Glaucoma is the world's first dual-target glaucoma treatment. Compared to current glaucoma medications, this eye-drop formulation achieves greater and more sustainable reductions of intraocular pressure by simultaneously inhibiting two key enzymes. It requires only one daily application, reducing side effects such as irritation and inflammation. Developed by TheratOcular Biotek and licensed to Metagone Biotech, this medication holds patents in the United States, the European Union, and Taiwan. This innovation marked Taiwan's first Edison gold victory for ophthalmic innovations in the health, medicine, and biotech category.